Vincerx Pharma, Inc. (VINCU) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Palo Alto, CA, United States.
VINCU has IPO date of 2020-12-29, 42 full-time employees, listed on the NASDAQ Global Select.
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.
